The FDA has approved istradefylline, an adenosine A2A receptor antagonist, as an adjunctive treatment to levodopa/carbidopa for Parkinson disease. Marketed as Nourianz, the drug is indicated for adults who experience "off" episodes — times when medications aren't working well, causing an increase in Parkinson's symptoms.
In four trials, patients treated with istradefylline had significantly less "off" time compared with those who took a placebo.
